RAF1 and cancer: While current targeted therapies like BRAFi and MEKi show varying levels of effectiveness across different cancer types, s substantial number of patients develop resistance relatively quickly.412 Ongoing cancer research is now actively addressing the challenge of countering both intrinsic and acquired drug resistance to small-molecule RAF inhibitors.